Oxford BioDynamics Plc (OBD) has announced that Vulpes Life Sciences Fund, controlled by Non-Executive Director Stephen Diggle, has sold 115,000 Ordinary Shares of 1 pence each at an average price of 45.2p. Following this transaction, Diggle is interested in a total of 28,333,756 shares, representing approximately 14.01% of the company's current issued share capital. The transaction was conducted on the London Stock Exchange.
Oxford BioDynamics Plc is a global biotechnology company that develops and commercializes precision medicine tests for life-changing diseases. Its flagship products include the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch PSE (EpiSwitch Prostate Screening test) blood tests. The CiRT test is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments, while the PSE test boosts the predictive accuracy of a PSA test for prostate cancer.
In addition to these tests, the company has also launched the EpiSwitch CST (Covid Severity Test) and the EpiSwitch Explorer Array Kit, a microarray kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics has partnered with big pharma companies and leading institutions, including Pfizer, Roche, and Mayo Clinic.
The company's product portfolio is based on its proprietary 3D genomic biomarker platform, EpiSwitch, which can build molecular diagnostic classifiers for predicting response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in various indications. Oxford BioDynamics is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange. It also has offices and laboratories in the US and Malaysia.
Overall, this news highlights a share transaction by a Non-Executive Director of Oxford BioDynamics Plc, reducing their shareholding in the company. It also provides an overview of the company's products and partnerships in the field of precision medicine testing.